Syndax Pharmaceuticals (SNDX) PT Lowered to $33 at UBS as Revuforj New Starts Decline

August 21, 2026 7:39 AM

UBS analyst David Dai lowered the price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $33.00 (from $37.00) while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found